-
公开(公告)号：US09804170B2
公开(公告)日：2017-10-31
申请号：US15018353
申请日：2016-02-08
Applicant: Bristol-Myers Squibb Company
Inventor： Murli Krishna , Alexander T. Kozhich , Martin J. Corbett , Zheng Lin , Steven P. Piccoli
CPC classification number: G01N33/6854 , C07K16/44 , C07K2317/24 , G01N2800/52
Abstract: Polyethylene glycol (PEG) is often conjugated with therapeutic proteins to enhance their PK properties. PEG may, however, be immunogenic, and the presence of PEG in food and cosmetics is believed to result in pre-existing anti-PEG antibodies in humans. Polyclonal and monoclonal antibodies reactive to PEG are provided for use in immunogenicity assay development to detect such anti-drug antibodies. Such antibodies exhibit preferential binding based on the size of PEG with molecular weight ranging from 350 daltons to 40 kD. Anti-PEG antibodies of the invention are engineered to comprise human Fc regions to enable non-bridging immunoassay formats.
-
公开(公告)号：US09662373B2
公开(公告)日：2017-05-30
申请号：US14632436
申请日：2015-02-26
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Sharon Cload , Linda Engle , Dasa Lipovsek , Malavi Madireddi , Ginger Chao Rakestraw , Joanna Swain , Wenjun Zhao , Alexander T. Kozhich , Martin J. Corbett
IPC: A61K39/395 , A61K38/39 , A61K47/48 , A61K38/17
CPC classification number: A61K38/39 , A61K38/00 , A61K38/17 , A61K38/1709 , A61K45/06 , A61K47/60 , A61K47/642 , C07K14/435 , C07K14/765 , C07K14/78 , C07K14/79 , C07K16/18 , C07K16/46 , C07K2319/30 , C07K2319/31 , G01N33/74
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
-
公开(公告)号：US09493546B2
公开(公告)日：2016-11-15
申请号：US14481641
申请日：2014-09-09
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Sharon Cload , Linda Engle , Dasa Lipovsek , Malavi Madireddi , Ginger Chao Rakestraw , Joanna Swain , Wenjun Zhao , Hui Wei , Aaron P. Yamniuk , Vidhyashankar Ramamurthy , Alexander T. Kozhich , Martin J. Corbett , Stanley Richard Krystek, Jr.
IPC: A61K38/00 , C07K1/00 , C07K14/00 , C07K17/00 , C07K16/00 , C12P21/08 , A61K35/14 , C07K14/78 , C07K16/46 , A61K38/39 , A61K47/48 , A61K45/06 , G01N33/74 , C07K14/435 , C07K14/765 , C07K14/79 , C07K16/18 , A61K38/17
CPC classification number: A61K38/39 , A61K38/00 , A61K38/17 , A61K38/1709 , A61K45/06 , A61K47/60 , A61K47/642 , C07K14/435 , C07K14/765 , C07K14/78 , C07K14/79 , C07K16/18 , C07K16/46 , C07K2319/30 , C07K2319/31 , G01N33/74
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
-
公开(公告)号：US11466092B2
公开(公告)日：2022-10-11
申请号：US16847130
申请日：2020-04-13
Applicant: Bristol-Myers Squibb Company
Inventor： Zhehong Cai , Indrani Chakraborty , Marie-Michelle Navarro Garcia , Thomas D. Kempe , Alan J. Korman , Alexander T. Kozhich , Hadia Lemar , Mark Maurer , Christina Maria Milburn , Michael Quigley , Xiang Shao , Mohan Srinivasan , Kent Thudium , Susan Chien-Szu Wong , Jochem Gokemeijer , Xi-Tao Wang , Han Chang , Patrick Guirnalda
IPC: A61K39/00 , A61K39/395 , G01N33/53 , C07K16/28 , C07K16/30 , A61P35/00 , G01N33/574
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
5.发明授权公开(公告)号：US08993265B2
公开(公告)日：2015-03-31
申请号：US14275542
申请日：2014-05-12
Applicant: Bristol-Myers Squibb Company
Inventor： Sharon Cload , Linda Engle , Dasa Lipovsek , Malavi Madireddi , Ginger Chao Rakestraw , Joanna Swain , Wenjun Zhao , Martin J. Corbett , Alexander T. Kozhich
IPC: C07H21/02 , C07H21/04 , C12P21/06 , C12N1/20 , C12N15/00 , C07K14/78 , C07K16/46 , A61K38/39 , A61K47/48 , A61K45/06 , G01N33/74 , C07K14/435 , C07K14/765 , C07K14/79 , C07K16/18
CPC classification number: A61K38/39 , A61K38/00 , A61K38/17 , A61K38/1709 , A61K45/06 , A61K47/60 , A61K47/642 , C07K14/435 , C07K14/765 , C07K14/78 , C07K14/79 , C07K16/18 , C07K16/46 , C07K2319/30 , C07K2319/31 , G01N33/74
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
Abstract translation: 本发明涉及结合肌生成抑制素的基于纤连蛋白的支架结构域蛋白。 本发明还涉及这些蛋白质用于治疗肌营养不良症，恶病质，肌肉减少症，骨关节炎，骨质疏松症，糖尿病，肥胖症，COPD，慢性肾脏疾病，心力衰竭，心肌梗死和纤维化的治疗应用中的用途。 本发明还涉及包含这种蛋白质的细胞，编码这种蛋白质或其片段的多核苷酸，以及包含编码蛋白质的多核苷酸的载体。
-
Patent Agency Ranking
6.发明授权公开(公告)号：US08853154B2
公开(公告)日：2014-10-07
申请号：US14025307
申请日：2013-09-12
Applicant: Bristol-Myers Squibb Company
Inventor： Sharon Cload , Linda Engle , Dasa Lipovsek , Malavi Madireddi , Ginger Chao Rakestraw , Joanna Swain , Wenjun Zhao , Hui Wei , Aaron P. Yamniuk , Vidhyashankar Ramamurthy , Alexander T. Kozhich , Martin J. Corbett , Stanley Richard Krystek, Jr.
IPC: A61K38/00 , A61P3/04 , A61K38/28 , A61P5/50 , A61P3/10 , A61P7/12 , A61P35/00 , C07K1/00 , C07K14/00 , C07K16/00 , C07K17/00 , C07H21/04 , G01N33/00 , C12N1/20 , C12N1/00 , C12P21/06 , C12N15/00 , C12N5/07 , C12N5/10 , C12N5/071 , G01N33/566 , A61K45/06 , C07K14/435 , A61K38/39 , C07K16/46 , G01N33/74 , A61K47/48 , C07K14/78
CPC classification number: A61K38/39 , A61K38/00 , A61K38/17 , A61K38/1709 , A61K45/06 , A61K47/60 , A61K47/642 , C07K14/435 , C07K14/765 , C07K14/78 , C07K14/79 , C07K16/18 , C07K16/46 , C07K2319/30 , C07K2319/31 , G01N33/74
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
Abstract translation: 本发明涉及结合肌生成抑制素的基于纤连蛋白的支架结构域蛋白。 本发明还涉及这些蛋白质用于治疗肌营养不良症，恶病质，肌肉减少症，骨关节炎，骨质疏松症，糖尿病，肥胖症，COPD，慢性肾脏疾病，心力衰竭，心肌梗死和纤维化的治疗应用中的用途。 本发明还涉及包含这种蛋白质的细胞，编码这种蛋白质或其片段的多核苷酸，以及包含编码蛋白质的多核苷酸的载体。
-
公开(公告)号：US10451634B2
公开(公告)日：2019-10-22
申请号：US15720073
申请日：2017-09-29
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Murli Krishna , Alexander T. Kozhich , Martin J. Corbett , Zheng Lin , Steven P. Piccoli
Abstract: Polyethylene glycol (PEG) is often conjugated with therapeutic proteins to enhance their PK properties. PEG may, however, be immunogenic, and the presence of PEG in food and cosmetics is believed to result in pre-existing anti-PEG antibodies in humans. Polyclonal and monoclonal antibodies reactive to PEG are provided for use in immunogenicity assay development to detect such anti-drug antibodies. Such antibodies exhibit preferential binding based on the size of PEG with molecular weight ranging from 350 daltons to 40 kD. Anti-PEG antibodies of the invention are engineered to comprise human Fc regions to enable non-bridging immunoassay formats.
-
公开(公告)号：US10406212B2
公开(公告)日：2019-09-10
申请号：US15491271
申请日：2017-04-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Sharon Cload , Linda Engle , Dasa Lipovsek , Malavi Madireddi , Ginger Chao Rakestraw , Joanna Swain , Wenjun Zhao , Alexander T. Kozhich , Martin J. Corbett
IPC: C07K14/00 , A61K38/39 , C07K14/78 , C07K16/46 , A61K45/06 , G01N33/74 , C07K14/435 , C07K14/765 , C07K14/79 , C07K16/18 , A61K38/17 , A61K47/64 , A61K47/60 , A61K38/00
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
-
公开(公告)号：US20180038872A1
公开(公告)日：2018-02-08
申请号：US15720073
申请日：2017-09-29
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Murli Krishna , Alexander T. Kozhich , Martin J. Corbett , Zheng Lin , Steven P. Piccoli
CPC classification number: G01N33/6854 , C07K16/44 , C07K2317/24 , C07K2317/33 , C07K2317/92 , G01N2800/52
Abstract: Polyethylene glycol (PEG) is often conjugated with therapeutic proteins to enhance their PK properties. PEG may, however, be immunogenic, and the presence of PEG in food and cosmetics is believed to result in pre-existing anti-PEG antibodies in humans. Polyclonal and monoclonal antibodies reactive to PEG are provided for use in immunogenicity assay development to detect such anti-drug antibodies. Such antibodies exhibit preferential binding based on the size of PEG with molecular weight ranging from 350 daltons to 40 kD. Anti-PEG antibodies of the invention are engineered to comprise human Fc regions to enable non-bridging immunoassay formats.
-
公开(公告)号：US10245302B2
公开(公告)日：2019-04-02
申请号：US15282277
申请日：2016-09-30
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Sharon Cload , Linda Engle , Dasa Lipovsek , Malavi Madireddi , Ginger Chao Rakestraw , Joanna Swain , Wenjun Zhao , Hui Wei , Aaron P. Yamniuk , Vidhyashankar Ramamurthy , Alexander T. Kozhich , Martin J. Corbett , Stanley Richard Krystek, Jr.
IPC: C12P21/02 , C07K14/78 , A61K38/39 , C07K16/46 , A61K45/06 , G01N33/74 , C07K14/435 , C07K14/765 , C07K14/79 , C07K16/18 , A61K38/17 , A61K47/64 , A61K47/60 , A61K47/48 , A61K38/00
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.029 seconds)
